the Safety and Efficacy of Ultra-fraction Radiotherapy Bridging CART Cell Therapy in Relapsed/Refractory Diffuse Large b Cell Lymphoma
Status: Recruiting
Location: See location...
Intervention Type: Radiation
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
This is a single-arm single center study to prospectively evaluate the safety and efficacy of ultra-fraction radiotherapy bridging CAR-T therapy in relapsed/refractory diffuse large b cell lymphoma
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Over than 18 years old
• Histologically confirmed DLBCL(by central pathology review before enrolment)
• Relapsed or refractory disease after ≥2 lines of chemotherapy including rituximab and anthracycline and either having failed autologous Hematopoietic stem cell transplantation (ASCT), or being ineligible for or not consenting to ASCT
• Measurable disease at time of enrollment (the maximum diameter of cross section ≥1.5cm)
• Life expectancy ≥12 weeks
• Able to receive radiotherapy evaluated by specialist
Locations
Other Locations
China
Peking Union Medical College Hospital
RECRUITING
Beijing
Contact Information
Primary
Jing Ruan, Docter
ruanjing@pumch.cn
+8615201435860
Time Frame
Start Date: 2022-09-01
Estimated Completion Date: 2024-12-01
Participants
Target number of participants: 20
Treatments
Experimental: treatment group
ultra-fraction radiotherapy + CAR-T
Related Therapeutic Areas
Sponsors
Leads: Peking Union Medical College Hospital